All News

A higher weight-adjusted waist index (WWI) was independently linked to greater all-cause and CVD mortality in CKD, partly via inflammation.

The ACCESS program gave underinsured patients free specialty eye care at one center, restoring vision and cutting disability costs, a study found.

CMS is withholding $9.8 billion in Texas Medicaid hospital funding tied to CHIRP, costing hospitals $27 million a day in a tax dispute.

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

A national study found comorbidities may drive worse long-term survival among patients with MASH awaiting or undergoing liver transplant.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

FDA approved zilganersen (ZANVASTRO), the first disease-modifying treatment for Alexander disease, based on pivotal trial data.

Despite positive data, the study authors call for prospective validation before PRO burden is incorporated into broader risk-stratification approaches.

Lung transplant candidates are aging rapidly, while cystic fibrosis decline in children shifts pediatric transplant toward sicker, more complex patients.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

A random survival forest model trained on 850 patients outperformed the Mayo Clinic and National Amyloidosis Centre staging systems for ATTR-CM.

Exposure prevention, primary care capacity, and digital health equity all shape the future of respiratory disease care.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.

COPD kills at rates rivaling heart failure and exceeding prostate and breast cancer, per a new study and US mortality data.

A deep learning model detected colorectal cancer on noncontrast CT with 86.6% to 88.2% real-world sensitivity.

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

gMG rescue therapy hinges on hospital access; grocery aid cuts diabetes complications; trials, CAR T strain oncology; myeloma faces logistics barriers.

Bioethicists say Kalshi's FDA and clinical trial betting markets risk bias, insider trading, and misleading signals about drug value.

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Keith Bellovich, DO, of Strive Health, discusses how the new CKM guideline unifies cardiology, nephrology, and endocrinology care.

August authors Jeff Romine, PhD, and Kofi Essel, MD, MPH, found grocery assistance linked to fewer diabetes complications and better medication adherence.

Bloating, abdominal pain, and tiredness were tied to clinical fear of recurrence in CRC survivors.

Whether these findings will translate into a change in treatment guidelines remains to be seen.

A researcher explains why cardiac diagnoses, not all-cause mortality, are the most reliable finding in her vaccine-safety study.

A randomized crossover trial found dose-dependent driving impairment from THC edibles at blood concentrations below common per se limits.

Five-year EXPLORER-LTE data show sustained LVOT gradient reductions and NYHA class improvements in patients with obstructive HCM.